BioStock: Oncoinvent strengthens board and cash position

Oncoinvent has appointed esteemed industry leaders to its Board of Directors, led by Gillies O’Bryan-Tear as Chairman. Furthermore, the company has completed a private placement round of NOK 71 million, which enables advancement to phase IIb with Radspherin. BioStock reached out to Gillies O’Bryan-Tear for a comment.

Read the full article at biostock.se:

https://www.biostock.se/en/2024/04/oncoinvent-strengthens-board-and-cash-position/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se